PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity.
Dominguez-Vigil I, Banik K, Baro M, Contessa J, Hayman T. PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity. Molecular Cancer Therapeutics 2025, of1-of12. PMID: 40296663, DOI: 10.1158/1535-7163.mct-24-0978.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerCFI-400945Mitotic catastropheNon-small cell lung cancer radiosensitizationRadiosensitivity of NSCLC cell linesCentrosome amplificationRadiation-induced tumor growth delayPLK4 inhibitionCell deathCurative-intent chemoradiationIncreased G2/M cell cycle arrestPolo-like kinase 4Subtype of lung cancerCell lung cancerIncreased centrosome amplificationCancer-related mortalityG2/M cell cycle arrestNSCLC cell linesCell cycle phase distributionClinical trial evaluationTargeting PLK4NSCLC in vitroCell cycle arrestPotential therapeutic target
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply